Stockscreener 앱 받기
1.37
7.03%
0.09
전일 마감가:
$1.28
열려 있는:
$1.28
하루 거래량:
2.90M
Relative Volume:
1.61
시가총액:
$497.86M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.7125
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
+17.09%
1개월 성능:
+14.17%
6개월 성능:
+6.20%
1년 성능:
+92.04%
1일 변동 폭
$1.26
$1.405
1주일 범위
$1.11
$1.405
52주 변동 폭
$0.2836
$1.66
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.37 | 465.15M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals (NASDAQ:LXRX) delivers shareholders notable 99% return over 1 year, surging 17% in the last week alone - simplywall.st
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Aug PreEarnings: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsQuarterly Market Summary & Expert Approved Momentum Trade Ideas - Bộ Nội Vụ
Published on: 2026-01-13 21:48:56 - Bộ Nội Vụ
Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain - marketscreener.com
Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference - marketscreener.com
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan
Published on: 2026-01-10 20:09:17 - ulpravda.ru
Lexicon Pharmaceuticals Releases White Paper on Addressing Chronic Pain with Non-Opioid Treatments Following Stakeholder Roundtable - Quiver Quantitative
MarketsMedicine Hat News - FinancialContent
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - Улправда
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - Улправда
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
How currency fluctuations impact Lexicon Pharmaceuticals Inc. stockWeekly Profit Summary & Stock Portfolio Risk Control - Улправда
Patterns Watch: Will Lexicon Pharmaceuticals Inc. stock outperform Dow Jones index2025 Fundamental Recap & Smart Allocation Stock Reports - moha.gov.vn
Investment Report: Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekers2025 Buyback Activity & Risk Managed Trade Strategies - Улправда
Lexicon Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
AI Stocks: Can Lexicon Pharmaceuticals Inc. stock beat market expectations this quarterVolume Spike & Real-Time Stock Movement Alerts - Улправда
Why Lexicon Pharmaceuticals Inc. stock is a must watch in 2025July 2025 Patterns & Entry Point Strategy Guides - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock weather global recessionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock rebound after recent weaknessWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - DonanımHaber
How Lexicon Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Final Week & AI Optimized Trade Strategies - DonanımHaber
Surprises Report: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsEarnings Growth Report & Daily Oversold Stock Bounce Ideas - Улправда
Is Lexicon Pharmaceuticals Inc. stock in correction or buying zone2025 Key Highlights & Real-Time Price Movement Reports - Улправда
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Trend Summary & Capital Efficient Trade Techniques - Улправда
Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money - simplywall.st
Short Covering: How risky is Lexicon Pharmaceuticals Inc stock now2025 Fundamental Recap & Community Verified Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon publishes preclinical data supporting LX9851 obesity treatment - StreetInsider
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 - Yahoo Finance
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
렉시콘 파마슈티컬스 주식 (LXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
4.73%
0.92%
자본화:
|
볼륨(24시간):